Cancer surveillance series: interpreting trends in prostate cancer - Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

Journal of the National Cancer Institute

Volumn 91, Issue 12, 1999, Pages 1033-1039

  Etzioni, Ruth ^a   Legler, Julie M ^b   Feuer, Eric J ^b   Merrill, Ray M ^c   Cronin, Kathleen A ^b   Hankey, Benjamin F ^b  

^a USA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CANCER TEST; COMPUTER MODEL; COMPUTER SIMULATION; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0033575099     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.12.1033     Document Type: Article

References (16)

1. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24.
2. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: Interpreting trends in prostate cancer - Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91:1025-32,
3. Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 1998;9: 519-27.
4. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
5. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan PC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993;42:365-74.
6. GAUSS Mathematical and Statistical System Version 3.2.18. Copyright 1994-1995. Maple Valley (WA): Aptech Systems Inc.; 1995.
7. National Center for Health Statistics. Vital statistics of the United States, 1986, Vol. II. Mortality Part A. DHHS Publ No. (PHS)88-1122. Washington (DC): US Govt Print Off; 1988.
8. SEER 1973-1994 public-use CD-ROM. Bethesda (MD): National Cancer Institute; 1997.
9. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
10. Pearson JD, Luderer AA, Metter EJ, Partin AW, Chao DW, Fozard JL, et al. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology 1996;48:4-9.
11. Morrell CH, Pearson JD, Carter HB, Brant LJ. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. JASA 1995;90:45-53.
12. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995;273:289-94.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York (NY): Wiley; 1980.
14. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994;152:1905-9.
15. Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3:97-104.
16. Yax LK (latest update - April 21, 1998). US Census Bureau, National Population Estimates [US Census Bureau homepage] [online]. Available: http://www.census.gov